| For: | Lv XY, Ding HG, Zheng JF, Fan CL, Li L. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World J Gastroenterol 2020; 26(2): 199-218 [PMID: 31988585 DOI: 10.3748/wjg.v26.i2.199] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v26/i2/199.htm |
| Number | Citing Articles |
| 1 |
Bradley Reuter, Jasmohan S. Bajaj. Microbiome. Clinics in Liver Disease 2020; 24(3) doi: 10.1016/j.cld.2020.04.006
|
| 2 |
Zhihao Lei. “Efficacy or illusion?” Interpreting null results in the rifaximin trial. Journal of Hepatology 2026; 84(2) doi: 10.1016/j.jhep.2025.08.012
|
| 3 |
T. E. Polunina. Risk stratification in alcoholic cirrhosis of the liver: a case study. Meditsinskiy sovet = Medical Council 2023; (8) doi: 10.21518/ms2023-129
|
| 4 |
Richard J Aspinall, Mark Hudson, Stephen D Ryder, Paul Richardson, Elizabeth Farrington, Mark Wright, Robert T Przemioslo, Francisco Perez, Melanie Kent, Roland Henrar, Joe Hickey, Debbie L Shawcross. Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II). Frontline Gastroenterology 2023; 14(3) doi: 10.1136/flgastro-2022-102221
|
| 5 |
Francisco Idalsoaga, Camila Robles, Andrea Ortiz, Oscar Corsi, Eduardo Fuentes-López, Luis Antonio Díaz, Gustavo Ayares, Marco Arrese, Juan Pablo Arab. Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy. Therapeutic Advances in Gastroenterology 2024; 17 doi: 10.1177/17562848241254267
|
| 6 |
Charles E. Gallaher, Debbie L. Shawcross. Management of Multidrug-Resistant Infections in Cirrhosis. Seminars in Liver Disease 2022; 42(02) doi: 10.1055/a-1765-0056
|
| 7 |
Jincheng Feng, Xueling Wang, Huan Cao, Yu Zhang, Jianjun Xu, Guoliang Wang, Xiaodan Zhu, Shenghe Deng. The Role of Lachnospiraceae in Liver Diseases: Recent Advances and Clinical Application Prospects. International Journal of Molecular Sciences 2026; 27(16) doi: 10.3390/ijms27167175
|
| 8 |
Kensuke Kitsugi, Kazuhito Kawata, Go Murohisa, Yashiro Yoshizawa, Masaharu Kimata, Yosuke Kobayashi, Shuhei Unno, Hidenao Noritake, Takeshi Chida, Yoshisuke Hosoda. C-Reactive Protein Levels Predict Improvement in the Liver Functional Reserve by Long-Term Rifaximin Treatment. Diseases 2025; 13(10) doi: 10.3390/diseases13100331
|
| 9 |
Xiaoli Hua, Hao Feng. Changes in intestinal microbiota of HBV-associated liver cirrhosis with/without hepatic encephalopathy. Medicine 2022; 101(33) doi: 10.1097/MD.0000000000029935
|
| 10 |
Roman Maslennikov, Aliya Alieva, Elena Poluektova, Yury Zharikov, Andrey Suslov, Yana Letyagina, Ekaterina Vasileva, Anna Levshina, Evgenii Kozlov, Vladimir Ivashkin. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota. World Journal of Gastroenterology 2023; 29(27): 4236-4251 doi: 10.3748/wjg.v29.i27.4236
Abstract(1246) |
Core Tip(1145) |
Full Article(HTML)(5931)
|
Full Article (PDF)-967K(508)
|
Full Article with Cover (PDF)-2077K(353)
|
Full Article (Word)-351K(78)
|
Full Article (XML)-396K(235)
|
Audio-395K(42)
|
Peer-Review Report-291K(233)
|
Answering Reviewers-97K(238)
|
Times Cited (27)
|
Total Visits (8858)
|
Open
|
| 11 |
Yunqi Xing, Yanghao Ou, Yujie Wang, Luming Hou, Junfeng Zhu. New insights into gut-liver axis in advanced liver diseases: A promising therapeutic target. Biochemical Pharmacology 2025; 242 doi: 10.1016/j.bcp.2025.117284
|
| 12 |
Xuemei Wang, Guanyue Su, Feilin Ge, Wenlong Miao, Lili Li, Zhe Li, Jia Yu, Hao Jiang, Yarong Ma, Zujiang Yu, Zhigang Ren, Hongxia Liang. Study of α-Amyrin targeting Sirt1/PGC-1α/PPARα axis to regulate fatty acid metabolism against liver fibrosis. Phytomedicine 2026; 159 doi: 10.1016/j.phymed.2026.158432
|
| 13 |
Paolo Caraceni, Victor Vargas, Elsa Solà, Carlo Alessandria, Koos de Wit, Jonel Trebicka, Paolo Angeli, Rajeshwar P. Mookerjee, François Durand, Elisa Pose, Aleksander Krag, Jasmohan S. Bajaj, Ulrich Beuers, Pere Ginès. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021; 74(3) doi: 10.1002/hep.31708
|
| 14 |
Aleksander Krag, Jasmohan S. Bajaj. Portal Hypertension VII. 2022; doi: 10.1007/978-3-031-08552-9_26
|
| 15 |
Jasmohan S Bajaj, Amirhossein Shamsaddini, Chathur Acharya, Andrew Fagan, Masoumeh Sikaroodi, Edith Gavis, Sara McGeorge, Alexander Khoruts, Michael Fuchs, Richard K Sterling, Hannah Lee, Patrick M Gillevet. Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis. Gut Microbes 2021; 13(1) doi: 10.1080/19490976.2021.1993584
|
| 16 |
Aldo Torre, Jacqueline Córdova-Gallardo, Alberto C Frati Munari. Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier. Therapeutics and Clinical Risk Management 2023; doi: 10.2147/TCRM.S425292
|
| 17 |
Ne’matjon Mamasoliev, Ibragim Askarov, Nasrulla Khakimov, Burkhonjon Usmonov, Oybek Umurzaqov, Bakhtiyor Nazarov, M.-T. Liong, I.V. Tkacheva. RETRACTED: Liver cirrhosis in the elderly population: analysing prevalence and gender characteristics within the biotechnological framework. BIO Web of Conferences 2024; 84 doi: 10.1051/bioconf/20248403004
|
| 18 |
Shi Heng , Peng Qin . Enhanced Spontaneous Bacterial Peritonitis Management in Cirrhosis: Peritoneal Lavage with Targeted Antibiotic
. International Journal of Gastroenterology 2025; 9(2) doi: 10.11648/j.ijg.20250902.13
|
| 19 |
Rui-fang Zhu, Yu-lu Gao, Sue-Ho Robert, Jin-ping Gao, Shi-gui Yang, Chang-tai Zhu. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19). Journal of Translational Medicine 2020; 18(1) doi: 10.1186/s12967-020-02442-5
|
| 20 |
Maria J. Duarte, Phyllis C. Tien, Ma Somsouk, Jennifer C. Price. The human microbiome and gut–liver axis in people living with HIV. Current HIV/AIDS Reports 2023; 20(3) doi: 10.1007/s11904-023-00657-x
|
| 21 |
Aanchal Bharti, Isar Sharma, Ritu Mahajan, Seema Langer, Nisha Kapoor. From Cirrhosis to the Dysbiosis (A Loop of Cure or Complications?). Indian Journal of Microbiology 2024; 64(3) doi: 10.1007/s12088-024-01267-w
|
| 22 |
Igor G. Bakulin, Inna A. Oganezova, Maria I. Skalinskaya, Ekaterina V. Skazyvaeva. Liver cirrosis and complication risk management. Terapevticheskii arkhiv 2021; 93(8) doi: 10.26442/00403660.2021.08.200917
|
| 23 |
Li Wang, Zheng-Min Cao, Li-Li Zhang, Juan-mei Li, Wen-liang Lv. The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.923599
|
| 24 |
Maha Mohammad Elsabaawy, Medhat Assem, Hanaa Badran, Asmaa Mahmoud, Dalia Elsabaawy, Amr Ragab. Impacts of rifaximin and midodrine on morbidity, mortality, and quality of life in patients with decompensated liver cirrhosis. European Journal of Gastroenterology & Hepatology 2024; 36(8) doi: 10.1097/MEG.0000000000002797
|
| 25 |
Yansheng Wang, Lulu Zhang, Huiping Wang, Qian Li, Furun An, Beibei Xie, Shuangwei Ying, Jinxiao Hou, Hui Qin, Zhimin Zhai, Fan Wu. Peritoneal effusion as a marker of disease severity in secondary hemophagocytic lymphohistiocytosis: Clinical and immunological insights. Sage Open Medicine 2026; 14 doi: 10.1177/20503121261487052
|
| 26 |
Paolo Caraceni, Juan G. Abraldes, Pere Ginès, Phil N. Newsome, Shiv K. Sarin. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. Journal of Hepatology 2021; 75 doi: 10.1016/j.jhep.2021.01.024
|
| 27 |
Weimiao Lin, Wenjin Fan, Lei Xu, Lihong Mao. Beyond conventional treatments: cutting-edge strategies for ascites in cirrhosis. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1918993
|
| 28 |
MohammadMahdi Saeidinejad, Ahmed Elshabrawi, Supachaya Sriphoosanaphan, Fausto Andreola, Gautam Mehta, Banwari Agarwal, Rajiv Jalan. Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure. Seminars in Liver Disease 2023; 43(04) doi: 10.1055/s-0043-1776773
|
| 29 |
Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Masashi Higashi, Takashi Miyayama, Tomotaka Higashi, Yotaro Uchida, Kumiko Shibata, Naoaki Tsuchiya, Atsushi Fukunaga, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites. Medicina 2022; 58(9) doi: 10.3390/medicina58091276
|
| 30 |
Kensuke Kitsugi, Kazuhito Kawata, Hidenao Noritake, Takeshi Chida, Kazuyoshi Ohta, Jun Ito, Shingo Takatori, Maho Yamashita, Tomohiko Hanaoka, Masahiro Umemura, Moe Matsumoto, Takafumi Suda. Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation. Journal of Clinical Medicine 2023; 12(6) doi: 10.3390/jcm12062210
|
| 31 |
Wanting Yang, Gaoyue Guo, Chao Sun. Therapeutic potential of rifaximin in liver diseases. Biomedicine & Pharmacotherapy 2024; 178 doi: 10.1016/j.biopha.2024.117283
|
| 32 |
Ruben Ladeira, Adrien Biguenet, Alexandre Meunier, Marion Gonthier, Vincent Di Martino, Anaïs Pitta, Edouard Bardou-Jacquet, Anne Jolivet-Gougeon, Maxime Desmarets, Thierry Thévenot, Didier Hocquet, Benoit Valot. Gut microbial dynamics and antibiotic resistance during rifaximin therapy in severe cirrhosis: a ProPILA-Rifax ancillary study. Frontiers in Cellular and Infection Microbiology 2026; 16 doi: 10.3389/fcimb.2026.1930709
|
| 33 |
Thomas H. Tranah, Victoria T. Kronsten, Debbie L. Shawcross. Implications and Management of Cirrhosis‐Associated Immune Dysfunction Before and After Liver Transplantation. Liver Transplantation 2022; 28(4) doi: 10.1002/lt.26353
|
| 34 |
Xiao Yu, Ye Jin, Wangxiao Zhou, Tingting Xiao, Zhongwen Wu, Junwei Su, Hainv Gao, Ping Shen, Beiwen Zheng, Qixia Luo, Lanjuan Li, Yonghong Xiao. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Frontiers in Cellular and Infection Microbiology 2022; 11 doi: 10.3389/fcimb.2021.761192
|
| 35 |
皓月 田. The Application of Rifaximin in Patients with End Stage Liver Disease. Advances in Clinical Medicine 2024; 14(01) doi: 10.12677/ACM.2024.141067
|
| 36 |
Mette Munk Lauridsen, Elise Jonasson, Jasmohan S. Bajaj. Microbial Approaches to Treat and Prevent Hepatic Encephalopathy. Gastroenterology Clinics of North America 2025; 54(2) doi: 10.1016/j.gtc.2024.12.006
|
| 37 |
Asiya Tafader, Jasmohan S. Bajaj. Present and future of fecal microbiome transplantation in cirrhosis. Liver Transplantation 2026; 32(1) doi: 10.1097/LVT.0000000000000542
|
| 38 |
Mei‐Tong Nie, Pei‐Qin Wang, Pei‐Mei Shi, Xia‐Lu Hong, Xin Zhang, Baoyu Xiang, Menghui Zhang, Wei‐Fen Xie. Rifaximin treatment shapes a unique metagenome‐metabolism network in patients with decompensated cirrhosis. Journal of Gastroenterology and Hepatology 2024; 39(4) doi: 10.1111/jgh.16484
|
| 39 |
Giacomo Zaccherini, Manuel Tufoni, Mauro Bernardi, Paolo Caraceni. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. Journal of Clinical Medicine 2021; 10(19) doi: 10.3390/jcm10194590
|
| 40 |
Fares E.M. Ali, Mustafa Ahmed Abdel-Reheim, Emad H.M. Hassanein, Mostafa K. Abd El-Aziz, Hanan S. Althagafy, Khalid S.A. Badran. Exploring the potential of drug repurposing for liver diseases: A comprehensive study. Life Sciences 2024; 347 doi: 10.1016/j.lfs.2024.122642
|
| 41 |
Vinay Jahagirdar, Jasmohan Singh Bajaj. Disease Modulating Agents in Cirrhosis. Clinics in Liver Disease 2026; 30(1) doi: 10.1016/j.cld.2025.08.008
|
| 42 |
Simona Parisse, Quirino Lai, Francesca Martini, Alice Martini, Flaminia Ferri, Monica Mischitelli, Fabio Melandro, Gianluca Mennini, Massimo Rossi, Domenico Alvaro, Stefano Ginanni Corradini. Rifaximin Reduces Risk of All-Cause Hospitalization in Cirrhotic Liver Transplant Candidates with Hepatic Encephalopathy. Journal of Clinical Medicine 2023; 12(21) doi: 10.3390/jcm12216871
|